A2 knocking at the door of the Top 10, ASX 100 indices
CFDA approval should spur A2's on-the-ground sales in China.
With Chinese regulatory approval now under its belt, A2 Milk is knocking on the door of another couple of milestones before year’s end – inclusion in some major indices.
The China Food & Drug Administration approval of its Chinese labelled infant formula should speed sales through physical
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Jenny Ruth
Mon, 02 Oct 2017
Mon, 02 Oct 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
A2 knocking at the door of the Top 10, ASX 100 indices
70505